Abstract:Background: Bone morphogenetic proteins (BMPs), members of the TGF-beta superfamily, are known to regulate cell proliferation, differentiation, apoptosis, chemotaxis, and angiogenesis. BMPs also participate in the development of most tissues and organs in vertebrates. Recombinant human (rh) BMPs, such as rhBMP-2, rhBMP-4, and rhBMP-7, have been recently approved to augment spinal fusion and recalcitrant long-bone non-unions because of their equivalent or superior efficacy to autogenous bone graft in enhancing bony fusion. Nonetheless, the use of BMPs is contraindicated in surgery for bone tumors because of concerns that this anabolic growth factor may cause tumor proliferation. However, we have repeatedly reported that BMP-2 is effective in inducing osteogenic differentiation of a subpopulation of osteosarcoma (OSA) cells that acquire stem cell attributes and are capable of reconstituting tumor masses, which in turn suppress the malignancy of the bone tumor. Methods: 3x10(5)/20 mu L, human OSA 143B cells were inoculated into 5-6 weeks old BABL/c nude mice to establish orthotopic OSA. X-ray device was used to monitor the developed tumors in animals. Necropsy was performed and the pathology of lung metastasis were tested by Haemotoxylin and Eosin. Moreover, bone formation induced by rhBMP-2 was investigated through micro-computed tomography. In addition, immunohistochemistry staining was used to evaluate the tumorigenicity and growth of OSA cells after rhBMP-2 treatment. Results: In the present study, we established an orthotopic model of OSA by inoculating 143B cells into BABL/c mice, which resulted in a tumor occurrence rate of 100%. Following the treatment with rhBMP-2, lung metastasis, which contributes to poor prognosis, was significantly restricted, indicating an additional aspect of rhBMP-2 to suppress expansion of OSA. Concurrently, our micro-computed tomography and radiographic analyses showed that rhBMP-2 reduced the invasion of tumor cells into adjacent bone tissue, which in turn helped to preserve the integrity of the affected bone tissue. Finally, the growth of Ki-67-positive cells and those cells that express high levels of aldehyde dehydrogenase (ALDH(br)) was found to be inhibited in the developed tumors. Conclusion: On the basis of these results, we conclude that rhBMP-2 can impede the malignancy of OSA by reducing lung metastasis of the tumor. Induction of the tumor cells by rhBMP-2 also helps to preserve the impaired skeleton. These results imply that BMP-2 or BMP-2-mimetic drugs, if properly combined with traditional therapies, may provide a new therapeutic option for the treatment of OSA.

Bispecific Antibody Suppresses Osteosarcoma Aggressiveness Through Regulation of NF-κB Signaling Pathway.

CD47 Blockade Inhibits Tumor Progression Human Osteosarcoma in Xenograft Models

The Role of CTLA-4 and PD-1 in Anti-Tumor Immune Response and Their Potential Efficacy Against Osteosarcoma

Hsa-miR-557 Inhibits Osteosarcoma Growth Through Targeting KRAS

Trim14 Regulates Cell Proliferation and Invasion in Osteosarcoma Via Promotion of the Akt Signaling Pathway

Inhibiting Bruton's Tyrosine Kinase to Counteract Chemoresistance and Stem Cell‐Like Properties in Osteosarcoma

BMP-2 inhibits lung metastasis of osteosarcoma: an early investigation using an orthotopic model.

Anti-CD166/4-1BB Chimeric Antigen Receptor T Cell Therapy for the Treatment of Osteosarcoma

N6-Methyladenosine Modification of the TRIM7 Positively Regulates Tumorigenesis and Chemoresistance in Osteosarcoma Through Ubiquitination of BRMS1

2-methylbenzoyl berbamine, a multi-targeted inhibitor, suppresses the growth of human osteosarcoma through disabling NF-κB, ERK and AKT signaling networks

TRIM26 Inhibited Osteosarcoma Progression Through Destabilizing RACK1 and Thus Inactivation of MEK/ERK Signaling.

TRIM59: A membrane protein expressed on Bacillus Calmette-Guérin-activated macrophages that induces apoptosis of fibrosarcoma cells by direct contact.

BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway

Targeting transforming growth factor beta signaling in metastatic osteosarcoma

Bromodomain Inhibition Attenuates the Progression and Sensitizes the Chemosensitivity of Osteosarcoma by Repressing GP130/STAT3 Signaling

PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse

Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B

Adenovirus-mediated Overexpression of BMP-9 Inhibits Human Osteosarcoma Cell Growth and Migration Through Downregulation of the PI3K/AKT Pathway.

Thiostrepton and Mir-216B Synergistically Promote Osteosarcoma Cell Cytotoxicity and Apoptosis by Targeting FoxM1

TBL 1 XR 1 promotes migration and invasion in osteosarcoma cells and is negatively regulated by miR-1865 p

Targeting RBM39 suppresses tumor growth and sensitizes osteosarcoma cells to cisplatin